Remove Antibody Remove Insulin Remove Licensing
article thumbnail

Provention faces delay in FDA review of diabetes prevention antibody

pharmaphorum

The issues are holding up discussions between the agency and company about labeling and post-marketing requirements for teplizumab, and are concentrated around the pharmacokinetics data for the antibody, and whether it is comparable to the drug that its original developer Eli Lilly entered into clinical trials.

article thumbnail

Provention Bio Launches Campaigns for Familial Type 1 Diabetes Screening

XTalks

Autoantibody screening involves measuring levels of islet autoantibodies (iAb) that recognize antigens found in insulin-producing pancreatic beta cells. Provention is developing an investigational anti-CD3 monoclonal antibody called PRV-031 (teplizumab), which is designed to delay onset, or prevent T1D in at-risk individuals.

Insulin 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Cyltezo Becomes First FDA-Approved Interchangeable Humira Biosimilar

XTalks

Boehringer Ingelheim’s Cyltezo has become the second interchangeable biosimilar approved by the FDA, and the first approved interchangeable monoclonal antibody. In July 2021, the agency approved the first interchangeable biosimilar product, Semglee (insulin glargine-yfgn) for the treatment of diabetes.

article thumbnail

Provention prices type 1 diabetes drug Tzield at $194,000

pharmaphorum

The company argues that the cost is justified as Tzield (teplizumab) is the first drug that can delay the onset of type 1 diabetes, fending off the time when they become highly reliant on insulins and at risk of the serious complications that can accompany advanced T1D. It also has an option on global marketing rights to the drug.

Drugs 116
article thumbnail

Biosimilars vs. Interchangeable Biological Products: FDA Fact Check

XTalks

They include proteins, monoclonal antibodies and vaccines that are considered to be “ highly similar ” to biological products that have already been approved by the FDA. What is a Biosimilar? Biosimilars are the “generic” drugs of the biopharma world.

article thumbnail

WHO announces international hub for mRNA vaccine training

pharmaphorum

The World Health Organization (WHO) announced the opening of a global biomanufacturing hub located in South Korea to provide training to low- and middle-income countries seeking to produce vaccines and other biologics, such as insulin and monoclonal antibodies. .

article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

2) Darzalex (daratumumab) Darzalex is a targeted monoclonal antibody that slows or stops the progression of multiple myeloma (a blood cancer) by binding to the CD38 protein on multiple myeloma cells. The monoclonal antibody targets CD20, a protein found on the surface of B lymphocytes (B cells). billion in 2022, a 32.44

Sales 98